Skip to main content
Leading the
Soft Mist Transition
Resyca BV is redefining drug delivery through innovative soft mist inhalation technology.

Founded as a joint venture between Medspray and Bespak, we specialise in developing drug-device combination products that improve therapeutic precision and patient experience.
Our platforms are designed to support pharmaceutical partners from early-stage development through to commercial launch.

Our Team
Our team is international, multidisciplinary, and deeply committed to advancing inhalation therapy.

With backgrounds in pharmaceutical sciences, engineering, clinical development, and regulatory affairs, we bring together the expertise needed to support complex combination product development. We collaborate globally—with partners in the EU, US, and Asia—and work closely with our clients to ensure their success from concept to commercialisation.

Experts
You Can Rely On

Learn More

We understand the complexity of inhalation and nasal delivered therapies. Our team combines deep scientific expertise with regulatory insight to deliver reliable, scalable solutions. Resyca’s technology is clinically validated and certified to meet global standards, including ISO 13485 and EU MDR.

Whether you’re developing a biologic, small molecule or nose-to-brain therapy, we provide the technical foundation and strategic support for your needs.


Responsible
and Conscientious

Learn More

We don’t overpromise. We deliver. Our approach is grounded in transparency, quality, and long-term thinking.

We take pride in being a trusted partner to pharmaceutical innovators, helping them navigate development challenges with confidence.


Collaborative
by Design

Learn More

Resyca is more than a technology provider—we’re a development partner. We work closely with pharma and biotech companies across Europe, North America, and Asia to co-create tailored solutions.

Our collaborations span formulation, device integration, clinical validation, and regulatory strategy. 


Agile
and Innovative

Learn More

We move fast, learn quickly, and solve problems with precision. Our proprietary platforms – Pulmospray® and PFSI™ – enable needle-free, soft mist delivery using standard pre-filled syringes.

These systems are compatible with GMP filling lines and suitable for pulmonary, nasal, and nose-to-brain applications.

Clinical validation demonstrates the therapeutic potential and reliability of our technology.


Resyca History
2020
Founded as a joint venture between Recipharm and Medspray.
2021

Clinical Phase IIb trial (NCT04990830): Heparin delivered via Pulmospray® improved oxygenation in COVID-19 patients.

2023

2023 Exclusive licence agreement with Pharma Partner on soft mist inhaler technology in pulmonary arterial hypertension

2023

Strategic collaboration with Stevanato Group to co-develop pre-fillable syringes for soft mist inhalers.

2024

Partnership with Aero Pump GmbH and Ursatec GmbH: launch of Ultra Soft Nasal Pump Spray for nose-to-brain and vaccine delivery.

2024

Collaboration with Silo Pharma on intranasal PTSD therapy using soft mist technology.

2024

Expansion of nasal drug delivery development program with Recipharm and Medspray.

2025

Exclusive license agreement with Cyrano Therapeutics for soft mist nasal spray to treat persistent loss of smell.

2025

EU MDR certification granted under Regulation (EU) 2017/745.

2025

CE mark of Pulmospray® MDR.

Partnerships

Key partnerships include Bespak, Medspray BV, Stevanato Group, Aero Pump GmbH, Ursatec GmbH, Cyrano Therapeutics, and Silo Pharma.

Your Breakthrough. Our Capabilities. Ready When You Are.
Resyca is here to support your journey.

Let’s shape the future of soft mist inhalation together.

Contact